Mortality Outcomes and Angiotensin-Converting Enzyme Inhibitor Use in Patients With Idiopathic Pulmonary Fibrosis
In this study, ACE inhibitor therapy was independently associated with reduced all-cause mortality in IPF but not in COPD. Prospective trials are warranted to confirm these findings in IPF populations.
Authors
- Kenan Direk (ORCID: https://orcid.org/0000-0001-9440-1638)
- Joseph Jacob (ORCID: https://orcid.org/0000-0002-8054-2293)
- Muhammad Qummer Ul Arfeen
- Burcu Özaltin (ORCID: https://orcid.org/0009-0009-2426-2607)
- Marie Vermant (ORCID: https://orcid.org/0000-0001-8546-8638)
- Robert Chapman (ORCID: https://orcid.org/0000-0003-0093-1086)
- Wim Wuyts (ORCID: https://orcid.org/0000-0001-9648-3497)
- Natalie Fitzpatick
- Harry Hemingway (ORCID: https://orcid.org/0000-0003-2279-0624)
- Tine Follet
Institutions
- University College Hospital (GB)
- Systems, Applications & Products in Data Processing (United Kingdom) (GB)
- Farr Institute (GB)
- The London College (GB)
- University College London (GB)
- Imperial College London (GB)
- KU Leuven (BE)
Publication Details
- Journal
- CHEST Journal
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1016/j.chest.2025.07.4077
- Citations
- 5
- Primary Topic
- Health and Well-being Studies
- Type
- article
- Field-Weighted Citation Impact
- 11.53
Funders
- GlaxoSmithKline
- Gilead Sciences
- Microsoft Research
- F. Hoffmann-La Roche
- Wellcome Trust